EVENTIDE ASSET MANAGEMENT, LLC
Position in AMLX — Amylyx Pharmaceuticals, Inc.
CIK 1442891
Boston, MA
Position in AMLX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$21,044,016
+$2,765,189 QoQ
Shares Held
1,513,958
+0.1% QoQ
Ownership
1.36%
of shares outstanding
% of Portfolio
0.35%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2022
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in AMLX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026EVENTIDE ASSET MANAGEMENT, LLC holds $107,290,135 across 5 Drug Manufacturers - Specialty & Generic names. AMLX ranks #3 (19.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | COLL |
Collegium Pharmaceutical, Inc
|
1,424,282 | $47,101,005 | |
| 2 | ADCT |
ADC Therapeutics SA
|
5,701,655 | $21,381,206 | |
| 3 | AMLX |
Amylyx Pharmaceuticals, Inc.
This page
|
1,513,958 | $21,044,016 | |
| 4 | UTHR |
UNITED THERAPEUTICS Corp
|
28,552 | $16,930,764 | |
| 5 | ZTS |
Zoetis Inc.
|
7,048 | $833,144 |
All Filings in AMLX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $21,044,016 | 1,513,958 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $18,278,827 | 1,513,148 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $20,554,875 | 1,512,500 | Shares | Sole | 2025-11-14 | |
| 2023-12-31 | $16,439,840 | 1,116,837 | Shares | Sole | 2024-02-20 | |
| 2023-09-30 | $20,449,285 | 1,116,837 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $24,090,174 | 1,116,837 | Shares | Sole | 2023-08-15 | |
| 2023-03-31 | $13,439,304 | 458,054 | Shares | Sole | 2023-05-15 | |
| 2022-12-31 | $9,237,500 | 250,000 | Shares | Sole | 2023-02-13 | |
| No filing history on record for this holder in this stock. | ||||||